Rockville's MacroGenics Inc. is moving deeper into the cancer immunotherapy space with a new big pharma partnership.

The clinical-stage biopharmaceutical company, which focuses on antibody-based therapies for cancer treatment and other diseases, announced it will work with Merck to study one of its molecules to treat stomach cancer. The companies will evaluate the antibody created by MarcoGenics in combination with Merck's immunotherapy drug Keytruda in a Phase 1b/2 clinical trial, officials said.

Vtesse, Inc. announced today the addition of Elizabeth Berry-Kravis, M.D., Ph.D., Professor of Pediatrics, Neurological Sciences and Biochemistry at Rush University Medical Center to its Scientific Advisory Board (SAB) and that Michael Massaro has joined the company as Vice President, Clinical Operations. Today’s news comes on the heels of Vtesse’s recent announcement that Rush University Medical Center has enrolled three patients in its pivotal Phase 2b/3 clinical trial with VTS-270 for treatment of Niemann-Pick Type C1 Disease (NPC). Vtesse expects up to 20 sites (across the United States and the European Union) to participate in this clinical trial.

“We seek SAB members who are both experienced clinicians and diligent researchers, and who also possess a strong passion to develop new treatment options and compassion for patients and their safety,” said Ben Machielse, Drs., President and Chief Executive Officer of Vtesse, Inc. “Dr. Berry-Kravis brings this unique combination to our SAB, which will support the clinical development of VTS-270. Her clinical research experience in rare diseases, such as Fragile X Syndrome, will help us advance our efforts with VTS-270. Dr. Berry-Kravis is serving as a co-lead principal investigator in our Phase 2b/3 clinical study of VTS-270 in addition to joining our SAB.”

MedImmune, a Greater Washington biotechnology cornerstone, is racing to fill the pipeline for parent AstraZeneca (NYSE: AZN) with drug candidates that harness the power of the immune system, even against cancer. And it's using precision medicine to do it.

GlaxoSmithKline and five other major drugmakers have teamed up with the UK government to launch the world’s first venture capital fund dedicated to finding new ways to prevent and treat dementia.

The Department of Health, the charity Alzheimer’s Research UK and the six pharmaceutical firms have raised $100m (£65m) to invest in early-stage, novel treatments for Alzheimer’s, Parkinson’s disease and other forms of dementia. GSK’s boss, Sir Andrew Witty, has been one of the main driving forces behind the initiative, in which the company is joined by the US drugmakers Johnson & Johnson, Biogen, Eli Lilly and Pfizer, and Japan’s Takeda.

Rockville-based health care IT provider DrFirst has secured $25 million in equity financing from Goldman Sachs, elevating its raise in the last year to $42 million.

DrFirst, which specializes in electronic prescription software services, said in a news release it will use the new investment to expand sales and marketing resources. It will also develop resources for new and existing products.

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received FDA approval for the cobas® HBV and cobas® HCV viral load tests, the first assays approved by the United States Food and Drug Administration (FDA) for use on the cobas® 6800 and cobas® 8800 Systems. The fully automated systems offer the fastest time to results, the highest throughput and the longest walk-away time available among automated molecular platforms, providing laboratories both improved operating efficiency and flexibility to adapt to changing testing needs. The new tests are the next generation of Roche's viral load tests, which clinicians use to manage the treatment of patients chronically infected with hepatitis B or hepatitis C virus.

UC San Francisco (UCSF) has launched a collaboration with international pharmaceutical company GlaxoSmithKline plc (GSK) to promote early-stage research with the potential to translate into new therapies for cancer, obesity and antibiotic resistant bacteria.

Through the collaboration, researchers from UCSF will work alongside GSK scientists to identify and jointly expedite promising basic research. In a shift from traditional sponsored-research agreements, the program will provide early-stage funding for validating academic discoveries that are not otherwise supported by traditional grant mechanisms.

Enthusiastic, animated, and innovative, Christopher Meenan left no doubt why he was among UMB’s 2015 Founders Week award winners with an insightful and entertaining Entrepreneur of the Year presentation “Health Informatics: A New Frontier for Innovation in Medicine” on Oct. 21.

Meenan, a faculty research associate in the School of Medicine’s Department of Diagnostic Radiology and Nuclear Medicine, recalled tales of his early career in the finance industry when Y2K was feared to be an “apocalyptic event” and later when he worked at America Online, which was striving “to be innovative” by putting 30 million people on the Internet.

138 Startups Now Compete for Fan Favorite and Finalist Designations Until Midday on Friday, November 6

Startup Maryland™ unveils the 138 video pitches from the participants in the 2015 Pitch Across Maryland competition. After posting the video pitches from Maryland entrepreneurs that were captured during the three-week Pitch Across Maryland bus tour, Startup Maryland is proud to announce that the two Video Pitch Competitions are now underway. You can find the various Playlists for each tour stop location where companies pitched on the Startup Maryland YouTube Channel.

The Startup Maryland bus rolled around the state for three weeks last month.

Mike Binko and company cruised through Baltimore with Steve Case’s Rise of the Rest tour, and made it over the Bay Bridge to Eastern Shore coworking space hotDesks.

One day featured a stop at Spark in Baltimore’s Power Plant Live! and the University of Baltimore. The bus was in Montgomery County, before heading back up to Charm City for Baltimore Innovation Week’s Beta City.

Georgetown University Biotechnology MS students seek unpaid internship in business or lab-related project in the Washington, DC metropolitan area. Students will spend minimum 280 hours (20hrs/week), Jan. 13 - Apr 22, 2016, and present a poster. For more info: contact Vasna Nontanovan, Associate Director, Biotechnology Masters Program, vn5@georgetown.edu, www.biotechnology.georgetown.edu.

The Seattle-based Microsoft Ventures Accelerator is a four-month program that connects startup founders with mentors and gives them the tools to help grow their business. The accelerator has 24 graduates to date, and is looking for its next class.

Specifically, Microsoft Ventures is looking for companies that focus on machine learning.

Free tasty food, brightly coloured bicycles and high salaries are well-known hallmarks of the Googleplex—Google’s famed headquarters in Mountain View, California. But it was not these perks that led cardiologist Jessica Mega to pause her thriving academic career at Harvard Medical School to become the chief medical officer of the company’s life-sciences team. She was lured by the ambitions of the effort, soon to be incorporated under Google’s parent firm Alphabet. Nurtured by Google’s expertise in data analytics and engineering, the biology team is expected to create miniaturized electronic devices and to use these and other means to collect and analyse more health data, more continuously, than is possible today.

Doctors have just discovered a previously unknown relationship between the long-term recovery of spinal cord injury victims and high blood pressure during their initial surgeries. This may seem like a small bit of medical news—though it will have immediate clinical implications—but what's important is how it was discovered in the first place.

This wasn’t the result of a new, long-term study, but a meta-analysis of $60 million worth of basic research written off as useless 20 years ago by a team of neuroscientists and statisticians led by the University of California San Francisco and partnering with the software firm Ayasdi, using mathematical and machine learning techniques that hadn’t been invented yet when the trials took place.

It's part of a a new program called Imprimis Cares that will make over 7,800 FDA-approved generic drugs available at an affordable price.

A pharmaceutical company announced Thursday that it plans to introduce a significantly lower-cost version of Daraprim, the drug that made headlines last month after jumping from $13.50 per pill to $750.

Nominations are now being accepted for the 2016 FLC awards. One of the most coveted honors in the technology transfer field, the FLC awards have been presented to over 200 federal laboratories since their inception in 1984. To reflect the diversity in scope and number of technology transfer efforts undertaken by federal laboratories and their partners, seven categories of awards will be presented.

Has venture capital always been a bad model for the life sciences?

Andrew Lo, director of the MIT Laboratory for Financial Engineering, dismissed the sector outright on stage Sunday at the Cleveland Clinic Medical Innovation Summit. His rationale:

Like Disney and the Dodgers before it, Cedars-Sinai is partnering on an industry-specific technology accelerator in Los Angeles. The nonprofit hospital in the Beverly Grove neighborhood has teamed on the first-ever Techstars Healthcare Accelerator.

The program will offer 10 entrepreneurs and startups in the global healthcare industry $120,000 in funding plus mentorship and guidance from senior leadership at Cedars-Sinai and access to Techstars’ network of more than 7,000 founders, mentors, investors and corporate partners. At the end of three months, the participating companies will participate in a demo day, presenting their work to investors, mentors, company executives and the community at large.

When Theranos founder Elizabeth Holmes agreed to be interviewed at the Wall Street Journal’s WSJ.D Live conference here in Laguna Beach, California, she didn’t know that the event would end up taking place a week after the Journal published an in-depth exposé charging that the company’s blood-testing system had serious problems and that it was actually using commercially available devices for much of its work.

In the process of raising money? Looking to refine your pitch for institutional investors? Join members of Camden Partners, Evergreen Advisors, and the Baltimore Angels to work on your presentation. We'll give you direct feedback on your presentation so that you're better positioned for both your elevator pitch, as well as formal pitches for investment.

The Maryland Innovation Initiative (MII) was created as a partnership between the State of Maryland and five Maryland academic research institutions (Johns Hopkins University, Morgan State University, University of Maryland College Park, University of Maryland Baltimore and University of Maryland Baltimore County.) The program is designed to promote commercialization of research conducted in the partnership universities and leverage each institution's strengths.